Back to today’s briefing

Story perspectives

FulcrumSec Withholds Novo Nordisk Trial Data After Refusing $25M Ransom

6/17/2026

34 6

Summary

Story summary

FulcrumSec will withhold data on Novo Nordisk’s production technology as a “harm-reduction” step.
Novo Nordisk disclosed the breach on June 11, stating its main platforms stay operational and that it is cooperating with authorities.
After refusing a $25 million ransom, FulcrumSec is exploring sales but will not release employee, physician or data on about 11,500 pseudonymised trial patients.

1 of 1

Story summary

FulcrumSec will withhold data on Novo Nordisk’s production technology as a “harm-reduction” step.
Novo Nordisk disclosed the breach on June 11, stating its main platforms stay operational and that it is cooperating with authorities.
After refusing a $25 million ransom, FulcrumSec is exploring sales but will not release employee, physician or data on about 11,500 pseudonymised trial patients.